Intelligence · Clinical Pipeline

Metabolic & obesity · Phase I

Metabolic & obesity programs at Phase I — ClinicalTrials.gov pipeline intelligence.

Programs: 159

Quick answer

Metabolic & obesity Phase I programs: NovaPharmaNews indexes 159 matching clinical development programs from ClinicalTrials.gov with sponsor, modality, and NCT cross-links.

Top sponsors

Huafu Shengji Ointment

Universal Integrated

Diabetic Foot

phase 1 small molecule active

1 trial
Humalog

HALOZYME THERAPEUTICS, INC.

Diabetes Mellitus

phase 1 small molecule completed

1 trial
ISIS 325568

IONIS PHARMACEUTICALS INC

Type 2 Diabetes Mellitus

phase 1 small molecule completed

1 trial
ISIS 388626

IONIS PHARMACEUTICALS INC

Type 2 Diabetes Mellitus

phase 1 small molecule completed

1 trial
Insulin Lispro

HALOZYME THERAPEUTICS, INC.

Diabetes Mellitus

phase 1 small molecule completed

1 trial
Insulin aspart

HALOZYME THERAPEUTICS, INC.

Type 1 Diabetes Mellitus

phase 1 small molecule completed

1 trial
Insulin degludec injection, RD15003

Sunshine Guojian Pharmaceutical (Shanghai) Co.,

Type 2 Diabetes

phase 1 mab completed

1 trial
Investigating how CagriSema, semaglutide and cagrilintide regulate insulin effects in the body of people with type 2 diabetes.

NovoThirteen

Type 2 diabetes

phase 1 other active

1 trial
Investigating how NNC0487-0111 regulates insulin in adults with type 2 diabetes

NovoThirteen

Type 2 Diabetes

phase 1 other active

1 trial
Investigation of pharmacokinetics, safety and tolerability of a single subcutaneous dose of NNC0487-0111 in participants with various degrees of renal impairment and normal renal function.

NovoThirteen

Obesity and Diabetes mellitus Typ 2

phase 1 other active

1 trial
LGD-6972

LIGAND PHARMACEUTICALS INC

Type 2 Diabetes Mellitus

phase 1 small molecule completed

2 trials
LGD-6972 Solution

LIGAND PHARMACEUTICALS INC

Type 2 Diabetes Mellitus (T2DM)

phase 1 small molecule completed

1 trial
LX4211

LEXICON PHARMACEUTICALS, INC.

Type 2 Diabetes Mellitus

phase 1 small molecule completed

2 trials
LY3532226

Eli Lilly and Company

Obesity

phase 1 small molecule completed

1 trial
Liraglutide injection,RD12014

Sunshine Guojian Pharmaceutical (Shanghai) Co.,

Type 2 Diabetes

phase 1 small molecule completed

1 trial
MBX 4291

MBX Biosciences

Obesity

phase 1 small molecule active

1 trial
MWN109 tablet

Shanghai University of Traditional Chinese Medicine

Overweight or Obesity

phase 1 small molecule active

1 trial
Metabolically Armed CD19 CAR-T cells

Anhui Provincial Hospital

Acute Lymphoblastic Leukemia

phase 1 small molecule active

1 trial
Metformin

The First People's Hospital of Lianyungang

Type2 Diabetes

phase 1 small molecule active

1 trial
Midazolam

ENANTA PHARMACEUTICALS INC

NASH

phase 1 small molecule completed

1 trial
Miricorilant

CORCEPT THERAPEUTICS INC

Non-alcoholic Steatohepatitis (NASH)

phase 1 small molecule completed

1 trial
Miricorilant 150 mg

CORCEPT THERAPEUTICS INC

Nonalcoholic Steatohepatitis (NASH)

phase 1 small molecule completed

1 trial
Mudan granule

Xiyuan Hospital of China Academy of Chinese Medical Sciences

Diabetic Peripheral Neuropathy Type 2

phase 1 small molecule active

1 trial
Multiple Dose Study of RO7795068 and its effect on Gastric Emptying, and on PK of Oral Contraceptives

Hoffmann-La Roche

Healthy Overweight or Obese

phase 1 other active

1 trial
NBI-6024

NEUROCRINE BIOSCIENCES INC

Type 1 Diabetes Mellitus

phase 1 small molecule completed

1 trial
NNC0480-0389

Novo Nordisk A/S

Healthy Volunteers Type 2 Diabetes

phase 1 small molecule completed

1 trial
Omega-3 fatty acids

NORTHWEST BIOTHERAPEUTICS INC

Metabolic Syndrome X

phase 1 other active

1 trial
Oshadi Oral Insulin

BRIGHT MINDS BIOSCIENCES INC.

Diabetes

phase 1 small molecule completed

1 trial
PF-05190457

Pfizer

Diabetes Mellitus, Type 2

phase 1 small molecule completed

1 trial
Phase I, single and multiple ascending dose, randomized, double-blind, placebo-controlled, parallel-group clinical trial to evaluate the safety, tolerability and pharmacokinetics of topical ocular administration of DS101 in healthy subjects.

The George Institute

Diabetic retinopathy.

phase 1 other active

1 trial
Phase I, single and multiple ascending dose, randomized, double-blind, placebo-controlled, parallel-group clinical trial to evaluate the safety, tolerability and pharmacokinetics of topical ocular administration of DS101 in healthy subjects.

The George Institute

Diabetic retinopathy.

phase 1 other active

1 trial
Placebo

Rhythm Pharmaceuticals Netherlands B.V.

Obesity

phase 1 small molecule completed

1 trial
ProHema-CB Transplant

Zafatek

Metabolic Disorders

phase 1 mab terminated

1 trial
REGN1193

Regeneron UK Limited

Diabetes Mellitus, Type 2

phase 1 small molecule terminated

1 trial
REGN1500

Regeneron UK Limited

Metabolic Disorders

phase 1 small molecule completed

1 trial
REGN20934

Regeneron UK Limited

Overweight or Obesity

phase 1 small molecule active

1 trial
RT-114 is the RaniPill capsule with PG-102 for the treatment of obesity

Rani Therapeutics Holdings

Obesity

phase 1 other active

1 trial
Randomised, crossover bioequivalence clinical trial of linagliptin/metformin 2.5 mg/1000 mg film-coated tablets, after a single oral dose administration to healthy volunteers under fed conditions.

Laboratorios Tillomed Spain S.L.U

diabetes

phase 1 other active

1 trial
Rongliflozin

Sunshine Guojian Pharmaceutical (Shanghai) Co.,

Type 2 Diabetes Mellitus

phase 1 small molecule completed

1 trial
Salvianolic Acid A

The First People's Hospital of Lianyungang

Neuropathy of Diabetes

phase 1 small molecule active

1 trial
Semaglutide Extended-release for Injectable Suspension, 1 mg

BRIGHT MINDS BIOSCIENCES INC.

Diabetes Mellitus, Type 2

phase 1 small molecule active

1 trial
TAK-329

Takeda

Type 1 Diabetes Mellitus

phase 1 small molecule completed

1 trial
TAK-648

Takeda

Type 2 Diabetes Mellitus

phase 1 small molecule completed

1 trial
Tebipenem Pivoxil Hydrobromide

Spero Therapeutics

Diabetes

phase 1 small molecule completed

1 trial
The Role of the Amylin Analogue Cagrilintide in Bone Metabolism

NovoThirteen

Female (aged between 50-70 years (both included)) with obesity (BMI ≥ 30.0 kg/m2) of post-menopausal state at screening (defined as minimum 12 months of amenorrhea and high levels of follicular stimulating hormone (FSH) ≥16 UI/L. In cases of uncertainty, confirmation of postmenopausal status requires low levels of anti-Müllerian hormone (AMH) and inhibin B).

phase 1 other active

1 trial
The pivotal bioequivalence study comparing the test product to the reference product, which belong to the group of medicines used in the treatment of type 2 diabetes mellitus when the condition cannot be adequately controlled by diet and exercise alone.

Lacuna Pharma Pty Ltd

Not applicable (submitted trial is a BE study in healthy subjects).

phase 1 other active

1 trial
The pivotal bioequivalence study comparing the test product to the reference product, which belongs to the group of medicines used in treatment of type 2 diabetes mellitus in adults and children aged 10 years and above, and heart failure and chronic kidney disease in adults patiens.

Lacuna Pharma Pty Ltd

Not applicable (submitted trial is a BE study in healthy subjects.

phase 1 other active

1 trial
UP421

Sana Biotechnology

Type1diabetes

phase 1 mab active

1 trial

Frequently asked questions

How many metabolic & obesity Phase I programs exist?

159 programs match both the therapeutic area and stage filters in our published index.

Data attribution: Data sources · All pipeline programs

Quick answer

Top sponsors

Huafu Shengji Ointment

Humalog

ISIS 325568

ISIS 388626

Insulin Lispro

Insulin aspart

Insulin degludec injection, RD15003

Investigating how CagriSema, semaglutide and cagrilintide regulate insulin effects in the body of people with type 2 diabetes.

Investigating how NNC0487-0111 regulates insulin in adults with type 2 diabetes

Investigation of pharmacokinetics, safety and tolerability of a single subcutaneous dose of NNC0487-0111 in participants with various degrees of renal impairment and normal renal function.

LGD-6972

LGD-6972 Solution

LX4211

LY3532226

Liraglutide injection,RD12014

MBX 4291

MWN109 tablet

Metabolically Armed CD19 CAR-T cells

Metformin

Midazolam

Miricorilant

Miricorilant 150 mg

Mudan granule

Multiple Dose Study of RO7795068 and its effect on Gastric Emptying, and on PK of Oral Contraceptives

NBI-6024

NNC0480-0389

Omega-3 fatty acids

Oshadi Oral Insulin

PF-05190457

Phase I, single and multiple ascending dose, randomized, double-blind, placebo-controlled, parallel-group clinical trial to evaluate the safety, tolerability and pharmacokinetics of topical ocular administration of DS101 in healthy subjects.

Phase I, single and multiple ascending dose, randomized, double-blind, placebo-controlled, parallel-group clinical trial to evaluate the safety, tolerability and pharmacokinetics of topical ocular administration of DS101 in healthy subjects.

Placebo

ProHema-CB Transplant

REGN1193

REGN1500

REGN20934

RT-114 is the RaniPill capsule with PG-102 for the treatment of obesity

Randomised, crossover bioequivalence clinical trial of linagliptin/metformin 2.5 mg/1000 mg film-coated tablets, after a single oral dose administration to healthy volunteers under fed conditions.

Rongliflozin

Salvianolic Acid A

Semaglutide Extended-release for Injectable Suspension, 1 mg

TAK-329

TAK-648

Tebipenem Pivoxil Hydrobromide

The Role of the Amylin Analogue Cagrilintide in Bone Metabolism

The pivotal bioequivalence study comparing the test product to the reference product, which belong to the group of medicines used in the treatment of type 2 diabetes mellitus when the condition cannot be adequately controlled by diet and exercise alone.

The pivotal bioequivalence study comparing the test product to the reference product, which belongs to the group of medicines used in treatment of type 2 diabetes mellitus in adults and children aged 10 years and above, and heart failure and chronic kidney disease in adults patiens.

UP421

Frequently asked questions

Stay Ahead in Pharma